Welcome to "Chronic Heart Failure: New Therapeutic Options for Improving Patient Outcomes.” A series of live CME-certified in-hospital presentations will be held at locations nationwide in 2017 and an on-demand webcourse will be available in early 2017.
In recent decades, an improved understanding of the pathobiology of heart failure (HF) has led to the introduction of a number of new classes of medications that have improved the clinical outcomes of HF patients. However, despite these advances, nearly 6 million people in the United States have HF. The 5-year mortality rate for HF remains unacceptably high at about 50%, and 30-day HF patient readmissions are ~25%. Although multiple therapies have been shown to lower mortality in patients with HF, their applications in clinical practice have been less than ideal. Chronic Heart Failure: New Therapeutic Options for Improving Patient Outcomes will review how to appropriately use newer and targeted treatment options as a means to optimize clinical outcomes in HF patients.
This activity is intended for cardiologists, internal medicine clinicians, and other allied healthcare professionals who participate in the continuum of care for patients with heart failure.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.